Presentation Title: Weight Loss with VI-0521 (Qnexa) Stops Progression Towards Type 2 Diabetes in Obese Non-Diabetic Subjects
Location: Louisiane C, Morial Convention Center
Presenter: Louis J. Aronne, MD
Date and Time: Monday, June 8, 2009, 4:30-6:30 P.M.
Session: New Treatments in Development
Presentation Title: One Year Treatment with VI-0521(Qnexa) in Type 2 Diabetes Demonstrates Continued Glycemic Improvement and Weight Loss
Location: Hall E-2, Morial Convention Center
Presenter: W. Timothy Garvey, MD
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are b
|SOURCE VIVUS, Inc.|
Copyright©2009 PR Newswire.
All rights reserved